Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.38 |
| ▸ | BRS3 | P32247 | 3/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7871095 | 0.91 | LTB4R2 (0.38) | ADRB1ADRB3LTB4R2SMN1; SMN2HPGD | |
| SCHEMBL7869050 | 0.81 | CYP1A2 (0.41) | HPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7869176 | 0.79 | FNTA (0.53) | — | |
| Mafenide SCHEMBL7862556 | 0.75 | FNTA (0.51) | — | |
| SCHEMBL7867498 | 0.74 | LTB4R2 (0.36) | ADRB1ADRB3LTB4R2SMN1; SMN2HPGD | |
| SCHEMBL7908229 | 0.73 | PTPN11 (0.35) | LTB4R2BRS3MCL1PPARGPPARA | |
| SCHEMBL10645940 | 0.73 | MEN1 (0.44) | ADRB1ADRB3SMN1; SMN2 | |
| SCHEMBL10648781 | 0.72 | LMNA (0.47) | RAB9A | |
| SCHEMBL7869070 | 0.72 | BCHE (0.50) | LTB4R2BRS3RARB | |
| SCHEMBL10645820 | 0.71 | CA12 (0.43) | ADRB1ADRB3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |